Defunct Company
Total Trials
41
As Lead Sponsor
0
As Collaborator
Total Enrollment
1,862
NCT00461552
Therapeutic Approaches to HAART-Induced Lipodystrophy
Phase: Phase 2
Role: Collaborator
Start: Jan 31, 2003
Completion: Sep 30, 2014
NCT00457938
Novel Therapies for Metabolic Complications of Lipodystrophies
Phase: N/A
Start: Apr 30, 2006
Completion: Nov 30, 2014
NCT00344851
Exenatide and Metformin Therapy in Overweight Women With PCOS
Start: Jun 30, 2006
Completion: Jun 30, 2007
NCT00353834
The Effect of Exenatide Compared to Lantus Insulin on Vascular Function in Type 2 Diabetes
Phase: Phase 4
Start: Aug 31, 2006
Completion: Sep 30, 2010
NCT00803920
Continuous Glucose Monitoring (CGM) in Subjects With Type 2 Diabetes Taking Twice-Daily Exenatide or Once-Weekly Exenatide
Start: Dec 31, 2006
Completion: Feb 29, 2008
NCT00842075
Pramlintide in Adolescents With Type 1 Diabetes
Completion: Dec 31, 2009
NCT00442767
Post-meal Insulin Dosing With Adjuvant Pre-meal Pramlintide in Children With Type 1 Diabetes Mellitus
Start: Feb 28, 2007
Completion: Feb 28, 2009
NCT00667732
How Glargine Insulin, Oral Diabetes Medications and Exenatide May Improve Blood Sugar Control and Weight Gain in Type 2 Diabetics
Start: Mar 31, 2007
Completion: Apr 30, 2010
NCT00876213
Amylin and Glucagon-Like Peptide-1 (GLP-1): Influence on Gastric Emptying, Appetite and Food Intake in Humans
Completion: Jun 30, 2008
NCT00456885
The Effect of Exenatide on Weight and Hunger in Obese, Healthy Women
Start: Apr 30, 2007
NCT00502138
A Pilot Study of Continuous Subcutaneous Pramlintide Infusion Therapy in Patients With Type 1 Diabetes
Start: Jul 31, 2007
Completion: Jan 31, 2008
NCT00460304
The Effect of Pramlintide on Meal Time Insulin Bolus
Start: Sep 30, 2007
Completion: Nov 30, 2008
NCT00529204
Effects Of Exenatide On Liver Biochemistry, Liver Histology And Lipid Metabolism In Patients With Fatty Liver Disease
Start: Oct 31, 2007
Completion: Feb 28, 2010
NCT00546728
The Vascular Effects of Exenatide Versus Metformin in Patients With Pre-Diabetes
Completion: Jul 31, 2011
NCT00690235
Demonstrate the Effects of Pramlintide on Weight Reduction in Schizophrenia
Start: Nov 30, 2007
Completion: Aug 31, 2011
NCT01006889
Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease
Start: Jan 31, 2008
NCT00710814
Trial of Leptin Administration After Roux-en-Y Gastric Bypass
Phase: Phase 1/2
Start: Apr 30, 2008
Completion: Jul 31, 2014
NCT00806520
Use of Continuous Glucose Monitoring Combined With Ambulatory Glucose Profiles to Characterize Glycemic Control
NCT01154933
Exeantide in Type 2 Diabetes on Insulin
Completion: Nov 30, 2011
NCT00855439
Evaluation of Exenatide in Patients With Diabetic Neuropathy
Start: Jun 30, 2008
Completion: May 31, 2014
NCT00736229
Intravenous Exenatide in Coronary Intensive Care Unit (ICU) Patients
Start: Aug 31, 2008
Completion: Aug 31, 2012
NCT00845559
The Effects of Exenatide on Post-Meal Sugar Peaks and Vascular Health in Obese/Pre-Diabetic Young Adults
Completion: Not specified
NCT01107717
Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM
Start: Jan 31, 2009
Completion: Feb 3, 2023
NCT00882050
Intravenous Exenatide (Byetta) During Surgery
Start: Mar 31, 2009
Completion: Apr 30, 2016
NCT00732147
Effects of Pramlintide on Endogenous Production of Very-low-density-lipoprotein (VLDL)-Triglyceride and Glucose in the Post Prandial State in T2DM
Start: Apr 30, 2009
Completion: Apr 30, 2011
NCT00790699
Safety Study of Using Symlin Alongside Insulin in a Multiple Injection Port
Start: Aug 31, 2009
NCT01165944
Effectiveness Study of Pramlintide to Treat Post-Transplant Diabetes Mellitus
NCT01061775
Effects of Exenatide on Hypothalamic Obesity
Start: Jan 31, 2010
Completion: Mar 15, 2019
NCT01137695
Efficacy Study of High Dose Symlin to Treat Type 2 Diabetes Mellitus
Phase: Phase 3
Start: May 31, 2010
Completion: Apr 30, 2012
NCT01588418
Acute Effect of Exenatide on Brain Glucose Metabolism
Start: Jul 31, 2010
Completion: Jul 31, 2015
NCT01147627
Effect of Different Interventions on Glycemic Control and β-cell Function in Newly Diagnosed Type 2 Diabetic Patients
Start: Aug 31, 2010
Completion: Dec 31, 2012
NCT01181986
The Study of Exenatide Action on Vessel Function in Type 2 Diabetes and Prediabetes
NCT01268644
Effects of Metreleptin in Type 1 Diabetes Mellitus
Phase: Phase 1
Start: Sep 30, 2010
Completion: Aug 31, 2014
NCT01364584
Impact of Exenatide on Cardiovascular Exercise Performance in Type 2 Diabetes
Start: Oct 31, 2010
Completion: Dec 31, 2014
NCT01381926
Changes in Bone Turnover With Exposure to a GLP-1 Receptor Agonist
Start: Feb 28, 2011
Completion: Aug 31, 2015
NCT01454973
Characterization of the Variability of Insulin Secretory Parameters in the Meal Tolerance and the Maximal Stimulation Tests of Healthy Subjects
Start: Oct 31, 2011
Completion: Jan 31, 2012
NCT01501084
Effects of the GLP-1 Exenatide on Satiety in Lean and Obese Women
Start: Dec 31, 2011
Completion: Feb 28, 2013
NCT01663207
Characterization of the Variability Of Insulin Secretory Parameters in the Meal Tolerance and the Maximal Stimulation Tests of Subjects With Prediabetes
Start: May 31, 2012
Completion: Apr 30, 2014
NCT01663220
Characterization of the Variability of Insulin Secretory Parameters in the Meal Tolerance and the Maximal Stimulation Tests of Subjects With Type 2 Diabetes Mellitus
NCT02346344
Outpatient Characterization of the Variability of Insulin Secretory Parameters in the Meal Tolerance and the Maximal Stimulation Tests of Subjects With Type 2 Diabetes Mellitus
Start: Apr 30, 2014
NCT02443922
Dynamic Responsiveness of Insulin Secretory Parameters To Sitagliptin and Glimeperide Administration in Type 2 DM
Start: Jun 30, 2015
Completion: Dec 31, 2015